Why Choose Private Prescription for Weight Management?
Private Prescription Advantages for Wegovy 1mg vs Mounjaro Comparison
When comparing Wegovy 1mg equivalent to Mounjaro through private prescription in the UK, you gain immediate access to both treatment options without the lengthy NHS pathway. The NHS route requires GP referral to specialist weight management services, often involving 6+ month waiting lists and strict eligibility criteria. Private prescription eliminates these barriers, allowing you to access the same prescription-only medicines through a streamlined 3-minute clinical assessment. Your dedicated prescriber can evaluate both Wegovy and Mounjaro based on your individual circumstances, medical history, and treatment preferences.
EverydayMeds provides both treatments through our GPhC-registered pharmacy (#9012878), ensuring you receive genuine manufacturer stock with full cold-chain delivery. This private route offers particular value for patients who've researched the Wegovy 1mg equivalent to Mounjaro comparison and want expert clinical guidance without NHS delays. Your prescriber can discuss mechanism differences, dosing schedules, and storage requirements to help determine which treatment aligns with your lifestyle and weight management goals.
Wegovy 1mg vs Mounjaro Pricing and Value Structure
Understanding the cost implications when comparing Wegovy 1mg equivalent to Mounjaro helps inform your private prescription decision. Wegovy 1mg pens cost £99.99 each, representing weeks 9-12 of the dose escalation protocol. New customers can apply code FIRST40 at checkout, while returning customers use code DOSE25 for additional savings. Our Advance Duo bundle (1mg + 1.7mg) is available for £269.99, providing seamless progression to the next dose tier without separate ordering.
Mounjaro pricing follows a different structure due to its unique dose escalation schedule, with both treatments requiring clinical assessment and prescription approval. The transparent pricing model eliminates hidden costs common with other private providers, and our next-day delivery service ensures consistent treatment continuity. When evaluating Wegovy 1mg equivalent to Mounjaro cost-effectiveness, consider the complete treatment pathway including dose escalation requirements and long-term maintenance pricing.
Clinical Evidence Supporting Wegovy 1mg in Comparative Context
The STEP clinical trial programme demonstrates Wegovy's efficacy at the 1mg dose level within the broader treatment protocol. In the landmark STEP 1 trial (Wilding et al., NEJM, 2021), patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks. The 1mg dose represents a crucial midpoint in the escalation schedule, where patients typically experience established appetite regulation and measurable progress.
When comparing Wegovy 1mg equivalent to Mounjaro evidence, both treatments have demonstrated significant efficacy in their respective clinical programmes, though direct head-to-head comparisons are limited due to different trial designs and populations. The SELECT cardiovascular outcomes trial showed Wegovy reduced major cardiovascular events by 20% (HR 0.80), highlighting benefits beyond weight management for appropriate patients under clinical supervision.
Understanding How Wegovy 1mg Works vs Mounjaro Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1 to reduce appetite and promote feelings of fullness after smaller meals. This mechanism works primarily on brain appetite centres, potentially reducing food cravings and supporting portion control when combined with dietary modifications. The 1mg dose provides substantial GLP-1 receptor activation while maintaining tolerability for most patients during the escalation phase. Mounjaro (tirzepatide) operates through a dual mechanism, targeting both GLP-1 and GIP receptors simultaneously, which may offer different appetite and metabolic effects. Both are prescription-only medicines requiring clinical supervision and must be used alongside a reduced-calorie diet and increased physical activity.
Private Prescription Ordering Process for Both Treatments
Accessing Wegovy 1mg equivalent to Mounjaro comparison through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, covering medical history, current medications, weight management goals, and previous treatment responses. Our qualified prescribers review your assessment within standard 3 working days (express 24-hour service available), evaluating suitability for both Wegovy and Mounjaro based on MHRA licensing criteria and clinical guidelines. Once approved, your chosen treatment ships via next-day cold-chain delivery with temperature monitoring to preserve medication integrity. The streamlined process eliminates traditional barriers while maintaining full clinical oversight and safety protocols. Our pharmacy team provides ongoing support throughout your treatment journey, including dose escalation guidance and re-ordering assistance.
Storage and Practical Considerations for Both Treatments
Wegovy offers practical storage advantages when comparing Wegovy 1mg equivalent to Mounjaro logistics, particularly for patients with active lifestyles or frequent travel requirements. Wegovy pens maintain stability for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage (2-8°C), compared to Mounjaro's 21-day room temperature limit. The FlexTouch pen design provides user-friendly injection experience with clear dose escalation markings and safety features. Both treatments require careful handling and proper disposal through pharmacy return schemes. The 1mg dose represents weeks 9-12 of Wegovy's protocol, requiring progression to 1.7mg and ultimately 2.4mg maintenance dosing unless clinical circumstances indicate otherwise. Storage flexibility can significantly impact treatment adherence and lifestyle integration for busy patients managing weight alongside work and family commitments.
Wegovy 1mg vs Mounjaro: Key Decision Factors for Private Patients
Private prescription patients comparing Wegovy 1mg equivalent to Mounjaro benefit from personalised clinical guidance without NHS resource constraints or standardised pathways. Key differentiators include mechanism of action (GLP-1 only vs dual GIP/GLP-1), dose escalation schedules, storage requirements, and individual response patterns based on medical history. Your prescriber can assess factors like diabetes risk, cardiovascular considerations, gastrointestinal tolerance, and lifestyle preferences to recommend the most appropriate option.
The private setting allows for flexible monitoring schedules, rapid dose adjustments if needed, and comprehensive support throughout the treatment journey. Both treatments require long-term commitment, as clinical trials demonstrate weight regain following discontinuation, making the choice between Wegovy and Mounjaro particularly important for sustainable outcomes. Private prescription ensures access to both options with expert clinical oversight tailored to your individual circumstances.
Secure Your Wegovy 1mg or Mounjaro Private Prescription Today
Ready to begin your clinically-supervised weight management journey with expert guidance on Wegovy 1mg equivalent to Mounjaro options? Complete our 3-minute assessment to connect with qualified prescribers who can evaluate both treatments based on your individual needs and medical profile. New customers can use code FIRST40 at checkout, while returning customers apply code DOSE25 for additional value on your private prescription. Visit our Wegovy 1mg product page to begin your assessment, with next-day delivery available once your prescription is approved. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine manufacturer stock with full clinical support throughout your treatment journey. Both Wegovy and Mounjaro are available through EverydayMeds — your prescriber can help determine which treatment aligns with your weight management goals and lifestyle requirements.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
